Skip to main content
main-content

13-02-2021 | ASCO GU 2021 | Conference coverage | Video

CheckMate 9ER update confirms benefits of nivolumab–cabozantinib in RCC

Cristina Suárez discusses additional efficacy findings, including data from the sarcomatoid subgroup, and quality of life results from the CheckMate 9ER trial of first-line nivolumab plus cabozantinib in patients with advanced renal cell carcinoma (5:58​).

Read transcript

Image Credits